Latest Pneumococcal conjugate vaccine Stories
Everything published by PLOS Medicine is open access: freely available for anyone to read, download, redistribute and otherwise use, as long as the authorship is properly attributed.
The use of 4 different 13-valent pneumococcal conjugate vaccine immunization schedules in healthy term infants resulted in no statistically significant differences in antibody levels between the infants after the booster dose at 12 months of age for almost all serotypes.
Children who receive a vaccine to prevent blood and ear infections, appear to be reducing the spread of pneumonia to the rest of the population, especially their grandparents and other older adults.
A new study led by researchers from Harvard School of Public Health (HSPH) and the Wellcome Trust Sanger Institute in the UK has, for the first time, used genome sequencing technology to track the changes in a bacterial population following the introduction of a vaccine.
RnRMarketResearch.com adds latest market research report on “Adult and Adolescent Vaccines Market to 2018 – Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use